Results for this period
Third quarter1 September 2025 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
The continued weak-yen environment, the resumption of Diamond Bar sales in China, higher sales in India, increased sales of Ailess needle-related products in Asia, and strong sales of surgical-related products in Europe, Japan and North America. The increase in revenue and the improvement in the cost-of-sales ratio resulting from the resumption of Diamond Bar sales absorbed the increase in expenses.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 September 2025 to 31 May 2026 |
| Net Sales | 24,396 Millions of yen (YoY +9.5%) |
| Operating profit | 7,486 Millions of yen (YoY +22.0%) |
| Ordinary income | 8,036 Millions of yen (YoY +33.3%) |
| Profit attributable to owners of the parent | 5,642 Millions of yen (YoY +32.6%) |
| Total assets | 62,474 Millions of yen |
| Net assets | 57,242 Millions of yen |
| Full-year earnings forecast | Net Sales 32,900 Millions of yen / Operating profit 9,700 Millions of yen / Ordinary income 10,150 Millions of yen / Net income 6,800 Millions of yen |
| Revision to Earnings Forecast | Net Sales 32,800 Millions of yen → 32,900 Millions of yen（+0.3%） / Operating profit 9,200 Millions of yen → 9,700 Millions of yen（+5.4%） / Ordinary income 8,950 Millions of yen → 10,150 Millions of yen（+13.4%） / Profit attributable to owners of the parent 6,450 Millions of yen → 6,800 Millions of yen（+5.4%） |
| Segment revenue | Surgical-related products 7,392 Millions of yen (YoY +6.0%), Ailess needle-related products 8,900 Millions of yen (YoY +6.8%), Dental Products 8,103 Millions of yen (YoY +16.2%) |
| Segment profit | Surgical-related products 2,557 Millions of yen (YoY +8.3%), Ailess needle-related products 3,454 Millions of yen (YoY +13.4%), Dental Products 1,473 Millions of yen (YoY +102.4%) |
| Regional sales | 3,706 Millions of yen, 11,630 Millions of yen, 4,720 Millions of yen, 2,241 Millions of yen, 2,097 Millions of yen |
| Depreciation and amortization | 1,825 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Insurance surrender value / Amount 16 Millions of yen, Item Gain on sale of non-current assets / Amount 3 Millions of yen / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount 0 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | The continued weak-yen environment, the resumption of Diamond Bar sales in China, higher sales in India, increased sales of Ailess needle-related products in Asia, and strong sales of surgical-related products in Europe, Japan and North America. The increase in revenue and the improvement in the cost-of-sales ratio resulting from the resumption of Diamond Bar sales absorbed the increase in expenses. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The weaker yen, which boosted overseas revenue, the resumption of Diamond Bar sales in China, higher sales in India, increased sales of Ailess needle-related products in Asia, and strong sales of surgical-related products in Europe, Japan and North America contributed to the increase in revenue. The increase in revenue and the improvement in the cost-of-sales ratio resulting from the resumption of Diamond Bar sales absorbed the increase in expenses, resulting in higher operating profit. The full-year forecasts were revised upward because the company assessed that Diamond Bar sales in China are highly likely to continue exceeding plan.